Insufficient scRNA-seq data for expression of CYP4F11 at tissue level.
Tissue | GTEx Coverage  | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
|---|---|---|---|---|---|---|
| liver | 100% | 5275.21 | 226 / 226 | 97% | 68.25 | 392 / 406 |
| prostate | 86% | 568.42 | 211 / 245 | 79% | 8.53 | 395 / 502 |
| brain | 89% | 390.48 | 2339 / 2642 | 64% | 4.84 | 449 / 705 |
| kidney | 85% | 587.00 | 76 / 89 | 62% | 9.61 | 563 / 901 |
| pancreas | 77% | 285.93 | 254 / 328 | 66% | 8.43 | 118 / 178 |
| stomach | 67% | 434.62 | 241 / 359 | 75% | 9.52 | 215 / 286 |
| esophagus | 52% | 632.62 | 745 / 1445 | 76% | 78.62 | 139 / 183 |
| bladder | 57% | 591.71 | 12 / 21 | 69% | 18.50 | 350 / 504 |
| thymus | 68% | 442.47 | 444 / 653 | 55% | 6.90 | 333 / 605 |
| intestine | 41% | 280.15 | 396 / 966 | 77% | 9.72 | 406 / 527 |
| breast | 46% | 146.91 | 213 / 459 | 53% | 5.98 | 595 / 1118 |
| lung | 37% | 84.57 | 214 / 578 | 57% | 49.17 | 662 / 1155 |
| blood vessel | 88% | 486.29 | 1172 / 1335 | 0% | 0 | 0 / 0 |
| adrenal gland | 70% | 406.07 | 181 / 258 | 12% | 1.13 | 28 / 230 |
| ovary | 7% | 11.05 | 12 / 180 | 72% | 9.00 | 308 / 430 |
| uterus | 12% | 29.28 | 21 / 170 | 58% | 11.71 | 264 / 459 |
| tonsil | 0% | 0 | 0 / 0 | 62% | 8.18 | 28 / 45 |
| spleen | 61% | 140.51 | 146 / 241 | 0% | 0 | 0 / 0 |
| skin | 32% | 57.17 | 573 / 1809 | 5% | 0.27 | 22 / 472 |
| muscle | 15% | 27.89 | 124 / 803 | 0% | 0 | 0 / 0 |
| adipose | 9% | 13.80 | 108 / 1204 | 0% | 0 | 0 / 0 |
| heart | 6% | 7.56 | 51 / 861 | 0% | 0 | 0 / 0 |
| eye | 0% | 0 | 0 / 0 | 3% | 0.12 | 2 / 80 |
| peripheral blood | 1% | 2.74 | 9 / 929 | 0% | 0 | 0 / 0 |
| abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| lymph node | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 29 |
| nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| ureter | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 1 |
| GO_0042377 | Biological process | vitamin K catabolic process |
| GO_0042376 | Biological process | phylloquinone catabolic process |
| GO_0019369 | Biological process | arachidonic acid metabolic process |
| GO_0007596 | Biological process | blood coagulation |
| GO_0042361 | Biological process | menaquinone catabolic process |
| GO_0006631 | Biological process | fatty acid metabolic process |
| GO_0097267 | Biological process | omega-hydroxylase P450 pathway |
| GO_1903604 | Biological process | cytochrome metabolic process |
| GO_0031408 | Biological process | oxylipin biosynthetic process |
| GO_0005789 | Cellular component | endoplasmic reticulum membrane |
| GO_0102033 | Molecular function | long-chain fatty acid omega-hydroxylase activity |
| GO_0016709 | Molecular function | oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, NAD(P)H as one donor, and incorporation of one atom of oxygen |
| GO_0004497 | Molecular function | monooxygenase activity |
| GO_0005506 | Molecular function | iron ion binding |
| GO_0005504 | Molecular function | fatty acid binding |
| GO_0020037 | Molecular function | heme binding |
| GO_0005515 | Molecular function | protein binding |
| GO_0070330 | Molecular function | aromatase activity |
| Gene name | CYP4F11 |
| Protein name | Cytochrome P450 4F11 (CYPIVF11) (EC 1.14.14.1) (3-hydroxy fatty acids omega-hydroxylase CYP4F11) (Docosahexaenoic acid omega-hydroxylase) (EC 1.14.14.79) (Long-chain fatty acid omega-monooxygenase) (EC 1.14.14.80) (Phylloquinone omega-hydroxylase CYP4F11) (EC 1.14.14.78) Cytochrome P450 family 4 subfamily F member 11 |
| Synonyms | |
| Description | FUNCTION: A cytochrome P450 monooxygenase involved in the metabolism of various endogenous substrates, including fatty acids and their oxygenated derivatives (oxylipins) . Mechanistically, uses molecular oxygen inserting one oxygen atom into a substrate, and reducing the second into a water molecule, with two electrons provided by NADPH via cytochrome P450 reductase (CPR; NADPH-ferrihemoprotein reductase) . Catalyzes with high efficiency the oxidation of the terminal carbon (omega-oxidation) of 3-hydroxy fatty acids, such as 3-hydroxyhexadecanoic and 3-hydroxyoctadecanoic acids, likely participating in the biosynthesis of long-chain 3-hydroxydicarboxylic acids . Omega-hydroxylates and inactivates phylloquinone (vitamin K1), and menaquinone-4 (MK-4, a form of vitamin K2), both acting as cofactors in blood coagulation . Metabolizes with low efficiciency fatty acids, including (5Z,8Z,11Z,14Z)-eicosatetraenoic acid (arachidonate) and its oxygenated metabolite 8-hydroxyeicosatetraenoic acid (8-HETE) . Catalyzes N- and O-demethylation of drugs such as erythromycin, benzphetamine, ethylmorphine, chlorpromazine, imipramine and verapamil . Catalyzes the oxidation of dialkylresorcinol 2 . . |
| Accessions | ENST00000620614.4 V9GYP6 ENST00000591841.1 ENST00000402119.9 ENST00000248041.12 ENST00000326742.12 Q9HBI6 F8W978 |
